DYRK3 and lymphoma: Future studies will show if it might be a potential pharmacological target in lymphomas, since a profiling of tyrosine phosphorylation in cancer cells identified Dyrk3 (and Dyrk1A) as prominently tyrosine –phosphorylated proteins in an anaplastic large cell lymphoma cell line, suggesting that these kinases might be abnormally activated in lymphoma cells [47].